326
Last Update Posted: 2017-05-04
Recruiting has ended
All Genders accepted | 18 Years-64 Years |
0 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1
The purpose of this study is to assess the clinical efficacy of the buprenorphine/naloxone combination tablet for alternate-day dosing and determine whether multiples of the daily dose are necessary to maintain an effective alternate day dosing regimen.
Alternate-day dosing with the 8mg buprenorphine-naloxone tablet is as safe and effective as daily dosing. Outcomes are improved when the total weekly dose provided during alternate-day dosing is equal to that given during daily dosing.
Eligibility
Relevant conditions:
Heroin Dependence
Opioid-Related Disorders
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov